• metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) 5
• mNSCLC - L2 - adenocarcinoma cell
• mNSCLC - L2 - all population 5
• mNSCLC - L2 - EGFR high
• mNSCLC - L2 - EGFR mutant 1
• mNSCLC - L2 - EGFR wild type
• mNSCLC - L2 - KRAS mutant
• mNSCLC - L2 - KRAS wild type
• mNSCLC - L2 - PDL1 negative 1
• mNSCLC - L2 - PDL1 positive 7
• non squamous cell - mNSCLC - L2
• non squamous - mNSCLC - L2 - all population 1
• non squamous - mNSCLC - L2 - EGFR mutant
• non squamous - mNSCLC - L2 - PDL1 positive
• non squamous - mNSCLC - L2 - wild type (WT)
• squamous cell - mNSCLC - L2
• squamous - mNSCLC - L2 - all population 1
• squamous - mNSCLC - L2 - PDL1 positive

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• avelumab based treatment
• avelumab alone
• durvalumab based treatment
• durvalumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (2mg/kg)

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs taxanes
• vs docetaxel
• vs Standard of Care (SoC)

  All patients

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

mNSCLC - L2 - PDL1 positive, durvalumab based treatment vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;